Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986527 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1: BMS-986527 monotherapy | EXPERIMENTAL | - |
| Cohort 2: BMS-986527 with Nivolumab | EXPERIMENTAL | - |
| Cohort 3: BMS-986527 with Cabozantinib | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986527 | DRUG | Specified dose on specified days |
| Nivolumab | DRUG | Specified dose on specified days |
| Cabozantinib | DRUG | Specified dose on specified days |
Inclusion Criteria * Participants must have a histologically confirmed diagnosis of a locally advanced and unresectable or metastatic renal cell carcinoma (RCC) with clear cell component. * Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Participa...
BMS-986527 is an investigational small molecule being developed by Bristol-Myers Squibb for clear cell renal cell carcinoma (ccRCC), a form of kidney cancer. It is in Phase 1 clinical development and has not been approved for any use. It is being studied as a potential treatment for patients with this cancer type.
BMS-986527 is being studied for the treatment of clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer. It is an investigational therapy in Phase 1 testing, so it is not yet available as a treatment outside of clinical trials. Its use in ccRCC remains under evaluation.
BMS-986527 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. Bristol-Myers Squibb is the sponsor of the clinical program evaluating the drug in clear cell renal cell carcinoma.
BMS-986527 is in Phase 1 clinical development. It is an investigational small molecule and has not been approved by the FDA or any other regulatory agency. The Phase 1 program is designed to assess safety and tolerability in participants with clear cell renal cell carcinoma.
BMS-986527 is being evaluated in one clinical trial, NCT07848295, titled A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC). The Phase 1 trial is not yet recruiting and plans to enroll 112 participants across the United States, Belgium, France, Germany, Italy, Netherlands, and Spain.
The Phase 1 trial NCT07848295 enrolls adults 18 years and older of all sexes with clear cell renal cell carcinoma. It does not accept healthy volunteers. The study is a controlled trial and is not yet recruiting, with a planned enrollment of 112 participants across seven countries.